CN102274223B - Compound preparation containing telmisartan and amlodipine - Google Patents
Compound preparation containing telmisartan and amlodipine Download PDFInfo
- Publication number
- CN102274223B CN102274223B CN201010199040A CN201010199040A CN102274223B CN 102274223 B CN102274223 B CN 102274223B CN 201010199040 A CN201010199040 A CN 201010199040A CN 201010199040 A CN201010199040 A CN 201010199040A CN 102274223 B CN102274223 B CN 102274223B
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- telmisartan
- coating
- pharmaceutically acceptable
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to a stable medicinal preparation composition containing telmisartan and amlodipine. The medicinal preparation composition containing telmisartan and amlodipine is characterized by comprising at least: (a) a core containing telmisartan or its pharmaceutically acceptable salt, wherein the core furtherly contains at least an alkaline material; (b) a coating containing amlodipine or its pharmaceutically acceptable salt. With telmisartan being in the core matrix, the telmisartan-containing core can be coated with a separating layer, and then amlodipine is coated on the telmisartan core with or without the separating layer by the adoption of a coating mode, wherein the coating matrix with amlodipine can further contain an acidic substance and the separating layer can further contain an acidic substance. The medicinal preparation composition prepared by the invention has good stability; simultaneously, its stability is further raised with the addition of the acidic substances into the separating layer and (or) amlodipine. The medicinal preparation composition provided by the invention has advantages of few auxiliary materials used, low cost and less preparation traits, and helps raise the patient compliance.
Description
Background of invention
Present hypertensive sickness rate is ascendant trend year by year, and the present situation of treatment is still very severe, and hypertensive control rate is still lower.Research shows that China adult's more than 18 years old hypertension prevalence is 18.8%, and number of patients surpasses 1.6 hundred million, and hypertensive awareness is 30.2%, and treatment rate is 24.7%, and control rate is 6.1%.The patient of as many as 2/3 needs drug combination to come controlling blood pressure.Two kinds of Most patients need or more medicine make blood pressure reach target, and patient especially higher to initial blood pressure, that have target organ damage or relevant disease more needs drug combination.Therefore hypertensive drug combination obtains everybody great attention.
Hypertension is cardiovascular diseases's independent hazard factor; Normal and insulin resistant, dyslipidemia, diabetes, overweight or fat merging exist; Relevant with cardiovascular and cerebrovascular vessel incidents such as apoplexy, coronary heart disease; Therefore make hyperpietic's blood pressure up to standard, can obviously reduce cardiovascular diseases's mortality rate and disability rate.But just because of hypertension is a kind of multifactorial disease, relate to many aspects such as renin angiotensin aldosterone system, sympathetic nervous system, body fluid capacity system, therefore wayward.Large-scale clinical research shows that the single therapy responder has only nearly 1/3.Single medicine can only be regulated hypertensive wherein a kind of mechanism, thus unsatisfactory curative effect, and can start feedback regulation mechanism after the blood pressure reduction; Blood pressure is gone up; Behind medicine dosage to the dose-response property platform, increase dosage again and can not increase curative effect, and cause untoward reaction to increase.Therefore can not the Satisfactory Control blood pressure to single therapy, or blood pressure level higher in, severe hypertension, should drug combination.
There are a lot of clinical trials to support the effective and good toleration of following drug regimen: diuretic and beta-blocker; Diuretic and ACEI; Diuretic and ARB; Dihydropyridine type calcium antagonists and beta-blocker; Calcium antagonist and ACEI; Calcium antagonist and ARB; Calcium antagonist and diuretic; α receptor blocking agent and beta-blocker.Also association center property depressor in case of necessity.Most diabetics are used two kinds of medicines at least.At a lot of hypertensive patients renal disease patients, the therapeutic alliance of 3 kinds of need or more different pharmaceutical minimum doses more than 90% is to reach the blood pressure desired value.Administration for ease, on the pharmaceutics often with two kinds of medication preparation in same unit formulation.But two kinds of different drug are prepared in a preparation, often need consider consistency problem.
WO2006048208 relates to the double-layer tablet of a kind of telmisartan and amlodipine; Patent obtains good dissolution in order to make telmisartan; Must comprise alkaline components for example sodium hydroxide or meglumine in the Telmisartan formulations; But when amlodipine when alkaline matter in the Telmisartan formulations directly contacts, the easy hydrolysis of the ester bond in the amlodipine molecule causes amlodipine stable inadequately.This patented technology mainly is to adopt the double-layer tablet technology, and when Amlodipine Besylate Tablet was contacted with alkaline matter, stability increased.
For example; The drug combination of Chinese patent CN1679954 telmisartan and amlodipine; Though its claim is a kind of composite antihypertensive preparation that contains telmisartan and calcium ion antagonist; But, has only the embodiment of drug combination owing to there is not the embodiment support of concrete compound preparation in its description.In fact, telmisartan and amlodipine being prepared into compound preparation is not to adopt that the general method of pharmacy just can success.
Though patent WO2006048208 has adopted double-layer tablet technology, still have amlodipine between amlodipine layer and the telmisartan layer and contact, in the process that double-layer tablet prepares with alkaline matter; Alkaline matter can pollute the amlodipine layer, still possibly cause amlodipine unstable, simultaneously; Double-layer tablet needs special bi-layer tablet press in the process of producing; Technological requirement is high, and yield is not high in the tabletting process, simultaneously because more at the adjuvant that needs owing to double-layer tablet; The sheet type is bigger, the poor compliance that the patient takes.
Research worker of the present invention is in the process of research; Adopt telmisartan and acceptable accessories to be prepared into core; Described telmisartan is in the substrate of core; The core that will contain telmisartan can the coating sealing coat, and to having or not having on the telmisartan core of sealing coat coating, described amlodipine is in coated substrate with the amlodipine coating for the mode that adopts coating then; A kind of acidic materials can be further contained in the coated substrate at amlodipine place, a kind of acidic materials can be further contained in the sealing coat.Adopt the pharmaceutical preparation combination of the present invention's preparation to have good stable property, simultaneously along with sealing coat with (or) the amlodipine layer adds acidic materials, stability further improves.And the adjuvant of the pharmaceutical preparation of the present invention's preparation is few, and the character of preparation is less, and cost is low, helps improving patient's compliance simultaneously.
Summary of the invention:
The present invention relates to a kind of telmisartan and amlodipine stabilised pharmaceutical compositions of containing, it is characterized in that containing at least (a) a kind of core that contains telmisartan or its pharmaceutically acceptable salt, contain a kind of alkaline matter in this core in addition at least.(b) a kind of coatings that contains amlodipine or its pharmaceutically acceptable salt;
Telmisartan of the present invention is following structure
Or its pharmaceutically acceptable salt, include but not limited to sodium salt and potassium salt.
The amlodipine structural formula that the present invention tells a story is:
Usually be present in the preparation with the acceptable salt of its pharmacy.
Its salt that pharmaceutically can connect includes but not limited to benzene sulfonate, maleate, mesylate.
Amlodipine of the present invention comprises the salt that Levamlodipine Besylate or its pharmacy are accepted.
The described core of this law can or be a micropill for tablet.
Of the present invention in the core that contains telmisartan with contain between the coated substrate of amlodipine and further contain one deck sealing coat, the sealing coat consumption is usual amounts pharmaceutically, and this area general technical staff can both understand.But its consumption can be optimized for the 0-20% of label or ball core weight, further is optimized for 1-10%.
Sealing coat of the present invention adopts material coating pharmaceutically commonly used, includes but not limited to HPMC, PVP, PVA and pharmaceutically acceptable additive.
The described sealing coat of this law can adopt art for coating coating pharmaceutically commonly used.
The described isolation coat layer of this law further contains a kind of pharmaceutically acceptable acidic materials at least.
At least contain a kind of pharmaceutically acceptable alkaline matter in the core that contains telmisartan of the present invention.
Pharmaceutically acceptable alkaline matter of the present invention has description at patent CN200810214445.4 and WO2006048208, includes but not limited to sodium hydroxide, potassium hydroxide, sodium bicarbonate, meglumine.
Alkaline matter of the present invention is pharmaceutically acceptable dosage or is common dose that its amount ranges has description at patent CN200810214445.4 and WO2006048208.
The coatings that contains amlodipine or its pharmaceutically acceptable salt of the present invention; Be meant that amlodipine or its pharmaceutically acceptable salt can be used in the substrate of filmogen of coating; Its preparation process is that amlodipine or its pharmaceutically acceptable salt are dispersed in the solution of filmogen, adopts art for coating coating pharmaceutically commonly used then.
The coatings that contains amlodipine or pharmaceutically acceptable salt of the present invention adopts coating material coating pharmaceutically commonly used; For instant capacity or speed collapse the type coating material; Include but not limited to HPMC, PVP, PVA and necessary additive; Can certainly adopt the good coating material of premix, for example Opadry series.
The coatings that contains amlodipine or its pharmaceutically acceptable salt of the present invention further contains pharmaceutically acceptable acidic materials.
Acidic materials of the present invention include but not limited to organic acid, and mineral acid, strong weak base salt, its consumption are pharmaceutically acceptable consumption or general consumption, are generally the 0-30% that contains the amlodipine coatings.
Acidic materials of the present invention are citric acid, phosphoric acid and phosphate, succinic acid, tartaric acid, maleic acid, benzenesulfonic acid.
Compositions of the present invention contains acceptable accessories.
Compositions of the present invention, the acceptable accessories that contains pharmacy includes but not limited to filler, disintegrating agent, binding agent, lubricant pharmaceutically commonly used.
Filler of the present invention includes but not limited to mannitol, sorbitol, lactose, microcrystalline Cellulose, starch, pregelatinized Starch.
Disintegrating agent of the present invention includes but not limited to low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, starch.
Alkaline matter of the present invention can mix in solution with telmisartan earlier, and spray drying obtains unformed telmisartan salt then.Unformed telmisartan salt and other mixing acceptable accessories adopt prepared pharmaceutically commonly used to become to contain the core of telmisartan, and core can be label, perhaps is micropill, perhaps is granule.
Alkaline matter of the present invention can be directly and telmisartan and its mixing acceptable accessories, adopts prepared pharmaceutically commonly used to become to contain the core of telmisartan, and core can be label, perhaps is micropill, perhaps is granule.
Tablet of the present invention can adopt pharmacy prepared commonly used, wet granule compression tablet technology for example, direct compression technology, adopt high-efficiency coating machine or fluidized bed coating coating sealing coat with (or) the amlodipine layer.
Micropill of the present invention can adopt Technology preparation pharmaceutically commonly used to contain the micropill of telmisartan through adopting telmisartan and acceptable accessories.For example, through extruding the micropill that the spheronization technique preparation contains telmisartan, also can be equipped with telmisartan through centrifugal granulating coating mechanism is micropill, also can contain the micropill of telmisartan through the technology preparation of celphere medicine-feeding.Adopt then centrifugal granulator coating machine or fluidized bed coating sealing coat with (or) the amlodipine layer.
Telmisartan of the present invention and amlodipine consumption are pharmacy consumption commonly used, in patent WO2006048208 and patent CN200510052246.4, detailed description are arranged about the dosage of telmisartan and amlodipine.
Telmisartan of the present invention or its salt and amlodipine or its pharmaceutically acceptable salt parts by weight pharmaceutically are following:
Telmisartan 20-160
Amlodipine 0.5-30.
Telmisartan of the present invention or its are pharmaceutically further optimized as follows with the parts by weight of amlodipine or its pharmaceutically acceptable salt:
Telmisartan 30-100
Amlodipine 2-20.
The specification of unit of the present invention pharmaceutical preparation is: telmisartan 40mg/ amlodipine 2.5mg; Telmisartan 40mg/ amlodipine 5.0mg; Telmisartan 40mg/ amlodipine 10mg; Telmisartan 80mg/ amlodipine 5mg, telmisartan 80mg/ amlodipine 10mg, telmisartan 80mg/ amlodipine 20mg.Preferred telmisartan 40mg/ amlodipine 5.0mg, telmisartan 40mg/ amlodipine 10mg, telmisartan 80mg/ amlodipine 5mg, telmisartan 80mg/ amlodipine 10mg.
Embodiment
Below be specific embodiment of the present invention, but do not represent that the present invention only limits to following examples.
Embodiment 1 (telmisartan 40mg/ amlodipine 2.5mg)
Preparation technology:
1) preparation label: with telmisartan, sodium hydroxide, mannitol mix homogeneously, the PVP solution of adding 10% is made soft material in right amount, and 24 eye mesh screens are granulated, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add stearic acid, mix homogeneously, and tabletting, every contains telmisartan 40mg.
2) coating amlodipine: HPMC, Pulvis Talci, titanium dioxide, PEG6000 are dissolved in the distilled water, add Amlodipine Besylate Tablet, dispersed with stirring.In high-efficiency coating machine, with the label coating, average every coating tablets is to amlodipine 2.5mg.
Embodiment 2 (telmisartan 40mg/ amlodipine 2.5mg)
Preparation technology:
1) preparation label: with telmisartan, sodium bicarbonate, mannitol mix homogeneously, the PVP solution of adding 10% is made soft material in right amount, and 24 eye mesh screens are granulated, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add stearic acid, mix homogeneously, and tabletting, every contains telmisartan 40mg.
2) coating amlodipine: HPMC, Pulvis Talci, titanium dioxide, PEG6000, citric acid are dissolved in the distilled water, add Amlodipine Besylate Tablet, dispersed with stirring.In high-efficiency coating machine, with the label coating, average every coating tablets is to amlodipine 2.5mg.
Embodiment 3 (telmisartan 40mg/ amlodipine 5mg)
Preparation technology:
1) preparation label: telmisartan, sodium hydroxide, meglumine, PVP is water-soluble, and spray drying with spray-dired product and mannitol mix homogeneously, adds an amount of purified water system soft material, the granulation of 24 eye mesh screens, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add stearic acid, mix homogeneously, and tabletting, every contains telmisartan 40mg.
2) coating of sealing coat: HPMC is dissolved in the distilled water, and with telmisartan label coating, average every coating tablets weightening finish 2% is equivalent to every coating tablets HPMC4.8mg in high-efficiency coating machine.
3) coating amlodipine: HPMC, PEG6000 are dissolved in the distilled water, add Amlodipine mesylate, dispersed with stirring.In high-efficiency coating machine, with the label coating, average every coating tablets is to amlodipine 5mg.
Embodiment 4 (telmisartan 40mg/ amlodipine 10mg)
Preparation technology:
1) telmisartan granule: with telmisartan, hydrogen sodium sodium, meglumine, PVP, sorbitol, mix homogeneously adds an amount of purified water system soft material, and 24 eye mesh screens are granulated, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add magnesium stearate, mix homogeneously, and tabletting, every contains telmisartan 40mg.
2) coating of sealing coat
The coating of sealing coat: HPMC E5 and citric acid are dissolved in the distilled water, and with telmisartan label coating, average every coating tablets weightening finish 2.4% is equivalent to every coating tablets HPMC4.8mg, citric acid 2.0mg in high-efficiency coating machine.
3) coating amlodipine: HPMC, PEG6000 are dissolved in the distilled water, add Amlodipine Besylate Tablet, dispersed with stirring.In high-efficiency coating machine, with the label coating, average every coating tablets is to containing amlodipine 10mg.
Embodiment 5 (telmisartan 80mg/ amlodipine 10mg)
Preparation technology:
1) preparation label: telmisartan, sodium hydroxide, PVP is water-soluble, and spray drying with spray-dired product and sorbitol mix homogeneously, adds an amount of purified water system soft material, the granulation of 24 eye mesh screens, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add magnesium stearate, mix homogeneously, and tabletting, every contains telmisartan 80mg.
2) coating of sealing coat: HPMC is dissolved in the distilled water, and with telmisartan label coating, average every coating tablets weightening finish 2% is equivalent to every coating tablets HPMC 9.6mg in high-efficiency coating machine.
3) coating amlodipine: HPMC, PEG6000 and maleic acid are dissolved in the distilled water, add Amlodipine Besylate Tablet, dispersed with stirring.In high-efficiency coating machine, with the label coating, average every coating tablets is to amlodipine 10mg.
Embodiment 6 (telmisartan 80mg/ amlodipine 5mg)
1) preparation label: telmisartan, sodium hydroxide, meglumine, PVP is water-soluble, and spray drying with spray-dired product and mannitol mix homogeneously, adds an amount of purified water system soft material, the granulation of 24 eye mesh screens, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add stearic acid, mix homogeneously, and tabletting, every contains telmisartan 80mg.
2) coating of sealing coat: PVA, PEG6000 and tartaric acid are dissolved in an amount of distilled water, homogenizing, with telmisartan label coating, average every coating tablets increases weight 2.0% in high-efficiency coating machine.
3) coating amlodipine: Opadry II is joined in the distilled water, stir, add Amlodipine Besylate Tablet then, homogenizing disperses, and obtains coating solution, in high-efficiency coating machine, with 2) resulting tablet coating, average every coating tablets is to amlodipine 5mg.
Embodiment 7 (telmisartan 80mg/ amlodipine 20mg)
1) preparation label: telmisartan, sodium hydroxide, meglumine and PVP is soluble in water, and spray drying with spray-dired product and mannitol mix homogeneously, adds an amount of purified water system soft material, and 24 eye mesh screens are granulated, 60 ℃ of dryings.24 order granulate obtain the telmisartan granule, add magnesium stearate, tabletting.Every contains telmisartan 80mg.
2) coating of sealing coat: HPMC, maleic acid, sodium dihydrogen phosphate are dissolved in the distilled water, homogenizing, with telmisartan label coating, average every coating tablets increases weight 2.2% in high-efficiency coating machine.
3) coating amlodipine: PEG-PVA and citric acid are joined in the distilled water, stir, add amlodipine maleate then; Homogenizing disperses, and obtains coating solution, in high-efficiency coating machine; With 2) resulting tablet coating, average every coating tablets is to amlodipine 20mg.
Embodiment 8 (telmisartan 40mg/ amlodipine 5mg)
Preparation technology:
1) preparation telmisartan ball core: with telmisartan, sodium hydroxide, PVP mix homogeneously, join 5% HPMC solution, adopt the spray of fluid bed side, the solution of above-mentioned telmisartan is sprayed on the celphere, obtain containing the telmisartan micropill.
2) sealing coat, in the HPMC aqueous solution with citric acid adding 5%, with telmisartan micropill coating sealing coat, the coating amount is about 10% of a telmisartan micropill.
3) coating amlodipine: HPMC, Pulvis Talci, titanium dioxide, PEG6000 are dissolved in the distilled water, add Amlodipine Besylate Tablet, dispersed with stirring.In fluid bed, with 2) resulting micropill coating amlodipine layer.Measure the content of telmisartan and amlodipine, filled capsules, specification is telmisartan 40mg/ amlodipine 5mg.
Comparative example's (telmisartan 40mg/ amlodipine 2.5mg, double-layer tablet)
1) telmisartan granule: telmisartan, sodium hydroxide, meglumine, PVP is water-soluble, and spray drying is with spray-dired product and mannitol; Mix homogeneously adds an amount of purified water system soft material, and 24 eye mesh screens are granulated; 60 ℃ of dryings; 24 order granulate, the magnesium stearate of adding recipe quantity, mix homogeneously.
2) Amlodipine Besylate Tablet granule: with Amlodipine Besylate Tablet, microcrystalline Cellulose, pregelatinized Starch mix homogeneously add purification of aqueous solutions and make soft material in right amount, wave granulation machine 24 eye mesh screens and granulate 60 ℃ of dryings, 24 order granulate.Add magnesium stearate, mix homogeneously.
3) adopt bi-layer tablet press tabletting, telmisartan layer 240mg, amlodipine layer 200mg.
Study on the stability:
Embodiment 1-8 and comparative example are investigated 6 months down in 40 ℃, adopt 0 month and the related substance in June of following chromatographic condition inspection amlodipine.Chromatographic column is C18, and mobile phase is 0.010mol/L dipotassium hydrogen phosphate solution (contain 0.7% triethylamine, phosphoric acid is transferred pH4.0 ± 0.1)-acetonitrile (70: 30), and flow velocity is 1.0ml/min, and the detection wavelength is 237nm, and sample size is 10 μ l.The result is following:
The result shows, adopts the embodiments of the invention related substance than the lacking of employing double-layer tablet, along with sealing coat or (with) adding of acidic materials, stability further improves, and explains that the present invention has advance more.
The preferred embodiments of the invention have been described in this article; The variation of these preferred versions can become obvious after reading above-mentioned explanation of the present invention for those of ordinary skill in the art; Therefore, the institute that the present invention includes the theme described in this paper accompanying claims changes and equivalent.
Claims (10)
1. stable pharmaceutical preparations composition that contains telmisartan and amlodipine is characterized in that containing at least:
(a) a kind of core that contains telmisartan or its pharmaceutically acceptable salt contains a kind of alkaline matter in addition at least in this core;
(b) a kind of coatings that contains amlodipine or its pharmaceutically acceptable salt.
2. pharmaceutical preparations composition according to claim 1, the core that contains telmisartan or its pharmaceutically acceptable salt and contain amlodipine or the coatings of its pharmaceutically acceptable salt between contain one deck sealing coat.
3. pharmaceutical preparations composition according to claim 1, wherein said core are the tablet that contains telmisartan or its pharmaceutically acceptable salt.
4. pharmaceutical preparations composition according to claim 1, wherein said core are the micropill that contains telmisartan or its pharmaceutically acceptable salt.
5. pharmaceutical preparations composition according to claim 1 wherein contains in the coatings of amlodipine or its pharmaceutically-acceptable salts and contains a kind of acidic materials in addition at least.
6. according to the said pharmaceutical preparation of claim 5, the percetage by weight of wherein said acidic materials in the amlodipine coatings is 0-30%.
7. pharmaceutical preparations composition according to claim 2, wherein sealing coat contains a kind of acidic materials at least.
8. according to the said pharmaceutical preparation of claim 7, its middle acid substance is 0-30% in the percetage by weight of sealing coat.
9. pharmaceutical preparations composition according to claim 1, described telmisartan or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable salt parts by weight are following:
Telmisartan 20-160
Amlodipine 0.5-30.
10. pharmaceutical preparations composition according to claim 9, described telmisartan or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable parts by weight are following:
Telmisartan 30-100
Amlodipine 2-20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010199040A CN102274223B (en) | 2010-06-12 | 2010-06-12 | Compound preparation containing telmisartan and amlodipine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010199040A CN102274223B (en) | 2010-06-12 | 2010-06-12 | Compound preparation containing telmisartan and amlodipine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102274223A CN102274223A (en) | 2011-12-14 |
| CN102274223B true CN102274223B (en) | 2012-10-24 |
Family
ID=45100170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010199040A Active CN102274223B (en) | 2010-06-12 | 2010-06-12 | Compound preparation containing telmisartan and amlodipine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102274223B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526048A (en) * | 2011-12-29 | 2012-07-04 | 南京华威医药科技开发有限公司 | Multi-layer coated tablet containing telmisartan and amlodipine |
| CN106619552B (en) * | 2017-01-04 | 2018-05-25 | 北京汇诚瑞祥医药技术有限公司 | A kind of telmisartan amlodipine fast-release tablet and preparation method thereof |
| CN110934848B (en) * | 2019-12-20 | 2022-02-15 | 江西杏林白马药业股份有限公司 | Telmisartan capsule and preparation method thereof |
| CN115944600A (en) * | 2022-12-01 | 2023-04-11 | 山东齐都药业有限公司 | Oral tablet containing telmisartan and amlodipine besylate and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679954A (en) * | 2005-01-18 | 2005-10-12 | 广东省人民医院 | Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use |
| CN101052381A (en) * | 2004-11-05 | 2007-10-10 | 贝林格尔·英格海姆国际有限公司 | Bilayer tablet comprising telmisartan and amlodipine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008059206A1 (en) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic |
-
2010
- 2010-06-12 CN CN201010199040A patent/CN102274223B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101052381A (en) * | 2004-11-05 | 2007-10-10 | 贝林格尔·英格海姆国际有限公司 | Bilayer tablet comprising telmisartan and amlodipine |
| CN1679954A (en) * | 2005-01-18 | 2005-10-12 | 广东省人民医院 | Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102274223A (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101539467B1 (en) | [45-] compositions suitable for oral administration comprising a triazolo [45-d]pyrimidin derivate | |
| CA2720658C (en) | Improved formulations for poorly permeable active pharmaceutical ingredients | |
| EP2413931B1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same | |
| KR101207618B1 (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| JP6122098B2 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof | |
| EP3566697A1 (en) | Tablet formulations of neratinib maleate | |
| CN103083318A (en) | Bilayer tablet comprising telmisartan and amlodipine | |
| TW200427448A (en) | Controlled release preparations comprising tramadol and topiramate | |
| EP2275093A2 (en) | Pharmaceutical formulation | |
| CN102085201A (en) | Atenolol and amlodipine bilayer tablet | |
| HUE033133T2 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| TW201206447A (en) | Pharmaceutical formulations | |
| JP6068765B2 (en) | Pharmaceutical combination preparation | |
| JP5517327B2 (en) | Composition for orally disintegrating tablets | |
| EP2854773B1 (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
| TW201014850A (en) | Solid pharmaceutical composition | |
| CN104010632A (en) | New combination | |
| CN102274223B (en) | Compound preparation containing telmisartan and amlodipine | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| KR20160105044A (en) | Solid composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
| TWI402083B (en) | Solid dosage form and stabilization method thereof | |
| KR101171375B1 (en) | Oral solid dosage form comprising poorly soluble drugs | |
| CN104814923A (en) | Tamsulosin Hydrochloride sustained-release preparation, preparation method and applications thereof | |
| PL236001B1 (en) | Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition, | |
| CN101797250A (en) | Stable compound preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |